tbuckley/cabot-search huggingface dataset:
Total Parenteral Nutrition in Malignancy
Authors: PAUL JAY FRIEDMAN
Journal: Annals of Internal Medicine (1985)

Letters and Corrections1 April 1985Total Parenteral Nutrition in MalignancyPAUL JAY FRIEDMAN, M.D.PAUL JAY FRIEDMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-4-556_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Shike and associates (1) showed that when total parenteral nutrition is used unnecessarily it raises the cost of medical care and prolongs hospitalization without corresponding benefit. On what basis did the Human Experimentation Committee at the University of Toronto approve aggressive nutritional support for patients at ideal body weight with initially trivial weight loss and adequate caloric intake to maintain body weight in sedentary subjects (1806 ± 131 kcal/d in controls)? As shown in Figure 4 (1), mortality at 6, 12, and 18 months was slightly higher in the study group than in controls. The substantial cost...References1. SHIKERUSSELDETSKY MDA. Changes in body composition in patients with small-cell lung cancer: the effect of total parenteral nutrition as an adjunct to chemotherapy. Ann Intern Med. 1984;101:303-9. LinkGoogle Scholar2. BLEILERSCHEDL RH. Creatinine excretion: variability and relationships to diet and body size. J Lab Clin Med. 1962;59:945-55. MedlineGoogle Scholar1. SHIKERUSSELLDETSKY MDA. Changes in body composition in patients with small-cell lung cancer: the effect of total parenteral nutrition as an adjunct to chemotherapy. Ann Intern Med. 1984; 101:303-9. LinkGoogle Scholar2. LANZOTTITHOMASBOYLE VDL. Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer. 1977;39:303-13. CrossrefMedlineGoogle Scholar3. RUSSELLSHIKEMARLISS DME. Effects of total parenteral nutrition and chemotherapy on the metabolic derangements in small cell lung cancer. Cancer Res. 1984;44:1706-11. MedlineGoogle Scholar4. BLEILERSCHEDL RH. Creatinine excretion: variability and relationships to diet and body size. J Lab Clin Med. 1962;59:945-55. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Medicine Waikato Hospital Hamilton New Zealand PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byA Key to the Literature of Total Parenteral Nutrition: Update 1987 1 April 1985Volume 102, Issue 4Page: 556-557KeywordsBody weightHospitalizationsMortalityNutritionTotal parenteral nutritionWeight loss Issue Published: 1 April 1985 PDF downloadLoading ...
The importance of acylation-stimulating protein levels in male patients with nonalcoholic liver diseases
Authors: S. Bagci, Z. Yesilova, A. Tuzun, Y. Ates, A. Uygun, A. Erdil, S. Tapan, M. Gulsen, N. Karaeren, K. Dagalp
Journal: Journal of Hepatology (2003)
Puerperal Eclampsia and its Treatment by Morphine
Authors: G. E. Fitzgerald
Journal: BMJ (1900)

MRDICAM JOURNAI '1AN1JT ature was zoo.60 F., the hiiglhest recorded during the illness; it dropped to °F. in the evening, and only once again reached I000 F., and that on the day following admission.The pulse was ioo, regular in force and rhythm.
ASSOCIATION OF CAROTID ATHEROSCLEROSIS AND C-REACTIVE PROTEIN WITH FUTURE CARDIOVASCULAR EVENTS IN CHRONIC HEMODIALYSIS PATIENTS
Authors: Toru Aoyama, Hideki Ishii, HIroshi Takahashi, Takanobu Toriyama, Toru Aoyama, Junji Watanabe, Masaaki Kanashiro, Satoshi Ichimiya, Toyoaki Murohara
Journal: Journal of the American College of Cardiology (2011)
Hormonal treatment of impetigo herpetiformis
Authors: M. GLIGORA, Z. KOLAVIO
Journal: British Journal of Dermatology (1982)

Journal Article Hormonal treatment of impetigo herpetiformis Get access M. GLIGORA, M. GLIGORA Department of Dermatology, Klinicka bolnica "Dr Z.Kucic", 51000 Rijeka, Yugoslavia Search for other works by this author on: Oxford Academic Google Scholar Z. KOLAVIO Z. KOLAVIO Department of Dermatology, Klinicka bolnica "Dr Z.Kucic", 51000 Rijeka, Yugoslavia Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 107, Issue 2, 1 August 1982, Page 253, https://doi.org/10.1111/j.1365-2133.1982.tb00353.x Published: 01 August 1982
CD13 is a therapeutic target in human liver cancer stem cells
Authors: Naotsugu Haraguchi, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Masahisa Ohkuma, Ho Min Kim, Hirofumi Akita, Daisuke Takiuchi, Hisanori Hatano, Hiroaki Nagano, Graham F. Barnard, Yuichiro Doki, Masaki Mori
Journal: Journal of Clinical Investigation (2010)

Cancer stem cells (CSCs) are generally dormant or slowly cycling tumor cells that have the ability to reconstitute tumors. They are thought to be involved in tumor resistance to chemo/radiation therapy and tumor relapse and progression. However, neither their existence nor their identity within many cancers has been well defined. Here, we have demonstrated that CD13 is a marker for semiquiescent CSCs in human liver cancer cell lines and clinical samples and that targeting these cells might provide a way to treat this disease. CD13+ cells predominated in the G0 phase of the cell cycle and typically formed cellular clusters in cancer foci. Following treatment, these cells survived and were enriched along the fibrous capsule where liver cancers usually relapse. Mechanistically, CD13 reduced ROS-induced DNA damage after genotoxic chemo/radiation stress and protected cells from apoptosis. In mouse xenograft models, combination of a CD13 inhibitor and the genotoxic chemotherapeutic fluorouracil (5-FU) drastically reduced tumor volume compared with either agent alone. 5-FU inhibited CD90+ proliferating CSCs, some of which produce CD13+ semiquiescent CSCs, while CD13 inhibition suppressed the self-renewing and tumor-initiating ability of dormant CSCs. Therefore, combining a CD13 inhibitor with a ROS-inducing chemo/radiation therapy may improve the treatment of liver cancer.
Abstract 3386: <i>In vivo</i> imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography
Authors: Viviane Mumprecht, Michael Honer, Benjamin Vigl, Steven Proulx, Eveline Trachsel, Manuela Kaspar, Nadja Banziger-Tobler, Roger Schibli, Dario Neri, Michael Detmar
Journal: Cancer Research (2010)

Abstract Metastasis to regional lymph nodes is a prognostic indicator for cancer progression. There is a great demand for sensitive and non-invasive methods to detect metastasis to the lymph nodes. While conventional in vivo imaging approaches have focused on the detection of cancer cells, lymphangiogenesis within tumor draining lymph nodes might be the earliest sign of metastasis. In mouse models of lymph node lymphangiogenesis, we found that systemically injected antibodies to lymphatic epitopes accumulated in the lymphatic vasculature in tissues and lymph nodes. Using a 124I-labeled antibody against the lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), we imaged, for the first time, inflammation-and tumor-draining lymph nodes with expanded lymphatic networks in vivo by positron emission tomography. This method might open up new avenues for the early detection of metastases and the images obtained might be used as biomarkers for the progression of diseases associated with lymphangiogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3386.
Role of lung fluid volume in growth and maturation of the fetal sheep lung.
Authors: A C Moessinger, R Harding, T M Adamson, M Singh, G T Kiu
Journal: Journal of Clinical Investigation (1990)

We studied the effects of alterations in lung fluid volume on growth and maturation of the fetal lung. In a chronic fetal sheep preparation, right fetal lung volume was decreased by drainage of lung fluid while the volume of the left lung was expanded by mainstem bronchus ligation leading to lung fluid retention. After an experimental period of 25 d (from 105 to 129 d of gestation, term = 145 d), the right (deflated) lung was significantly hypoplastic and contained less DNA than the controls; 175.15 +/- 55.18 vs. 346.77 +/- 61.97 mg, respectively; P less than 0.001. In contrast, the left (expanded) lung was significantly hyperplastic and contained more DNA than the controls; 390.74 +/- 103.53 vs. 238.85 +/- 33.32 mg, respectively; P = 0.001. Biochemical indices of lung maturation, including total phospholipids, phosphatidylcholine, and disaturated phosphatidylcholine content expressed per unit of tissue DNA, were no different when comparing the hypoplastic, hyperplastic, and control lungs. These findings demonstrate that fetal lung cell multiplication is influenced by local distension with lung fluid, while the biochemical maturation of fetal lung surfactant is under systemic control.
Computing the motor-sensor map
Authors: Oswald Wiener, Thomas Raab
Journal: Behavioral and Brain Sciences (2004)

“Articulate models” subservient to formal intelligence are imagined to be heterarchies of automata capable of performing the “symbolic (quasi-spatial) syntheses” of Luria (1973), where “quasi-spatial” points to the abstract core of spatiality: the symbol productions, combinations, and substitutions of algebraic reckoning. The alleged cognitive role of internal “topographic images” and of “efference copies” is confronted with this background and denied.
Rapid and Parallel Chromosomal Number Reductions in Muntjac Deer Inferred from Mitochondrial DNA Phylogeny
Authors: Wen Wang, Hong Lan
Journal: Molecular Biology and Evolution (2000)

Muntjac deer (Muntiacinae, Cervidae) are of great interest in evolutionary studies because of their dramatic chromosome variations and recent discoveries of several new species. In this paper, we analyze the evolution of karyotypes of muntjac deer in the context of a phylogeny which is based on 1,844-bp mitochondrial DNA sequences of seven generally recognized species in the muntjac subfamily. The phylogenetic results support the hypothesis that karyotypic evolution in muntjac deer has proceeded via reduction in diploid number. However, the reduction in number is not always linear, i.e., not strictly following the order: 46→14/13→8/9→6/7. For example, Muntiacus muntjak (2n = 6/7) shares a common ancestor with Muntiacus feae (2n = 13/14), which indicates that its karyotype was derived in parallel with M. feae's from an ancestral karyotype of 2n ≥ 13/14. The newly discovered giant muntjac (Muntiacus vuquangensis) may represent another parallel reduction lineage from the ancestral 2n = 46 karyotype. Our phylogenetic results indicate that the giant muntjac is relatively closer to Muntiacus reevesi than to other muntjacs and may be placed in the genus Muntiacus. Analyses of sequence divergence reveal that the rate of change in chromosome number in muntjac deer is one of the fastest in vertebrates. Within the muntjac subfamily, the fastest evolutionary rate is found in the Fea's lineage, in which two species with different karyotypes diverged in around 0.5 Myr.
Decreased transepicardial dispersion of repolarisation in hypertrabeculation/noncompaction cardiomyopathy patients
Authors: Hatice Betül Erer, Tolga Sinan Güvenç, Servet Altay, Elif İclal Çekirdekçi, Nazmiye Özbilgin, Nurten Sayar, Dilaver Öz, Ahmet Ekmekçi, Aycan Zencirci, Gönül Zeren, Osman Şahin, Ahmet Lütfü Orhan, Mehmet Eren
Journal: Journal of the American College of Cardiology (2013)
Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus
Authors: Peter J. Kretschmer, Fang Jin, Cecile Chartier, Terry W. Hermiston
Journal: Molecular Therapy (2005)

Therapeutic gene delivery from an oncolytic adenovirus (Ad) is one approach to enhancing the potency of Ad-based virotherapies for cancer. To identify therapeutic transgene insertion sites compatible with the replicating virus, a methodology that broadly scans the viral genome is needed. To address this we modified a transposon (Tn7)-based in vitro transposition system to take advantage of its nonprejudiced scanning ability to identify insertion sites compatible with viral replication. Using this system with a plasmid containing an E3-deleted Ad5, we identified several unique sites for promoter-based expression cassette insertions within the Ad genome. The transposon-based expression cassette is bounded by PmeI restriction endonuclease sites unique to the transposon, making expression cassette substitutions easy to perform. Additional expression cassettes containing different promoters and reporter genes were substituted into two of the newly identified transgene insertion sites. The results suggest that the ease and orientation of expression cassette substitution depend on both the insertion site location and the promoter and gene of the replacement expression cassette. These studies establish the transposon-based system as an efficient approach to scanning the Ad genome and identifying insertion sites compatible with viral replication and represents a powerful tool for the development of armed therapeutic viruses for cancer.
Fine-Needle Aspiration of Malignant Hepatic Nodules for Cytodiagnosis
Authors: Alfred L. Hurwitz
Journal: JAMA (1974)

The cytologic diagnosis of metastatic carcinoma of the liver was established in two patients by fine-needle aspiration of hepatic nodules. The aspiration was successful despite lack of cooperation by one patient. The other patient had had a standard transthoracic liver biopsy that was not diagnostic for metastatic carcinoma. Peritoneoscopy would have been a difficult procedure with either patient. Fine-needle aspiration of the liver may be a useful adjunct to standard liver biopsy and may prevent peritoneoscopy or exploratory laparotomy with certain patients. (<i>JAMA</i>229:814-815, 1974)
Abstract 1401: SYK promotes tumor progression in ovarian cancer cell lines
Authors: Aya Sultan, Cindy Y. Wang, George E. Duran, E. Brian Francisco, Jonathan S. Berek, Branimir I. Sikic
Journal: Cancer Research (2011)

Abstract Identification of novel drug targets in ovarian cancers has focused on expression of genes in the tyrosine kinase family. We have previously shown that the spleen tyrosine kinase (SYK) gene was expressed in 73% of 55 ovarian cancer specimens, compared to 26% of 60 breast cancer specimens. Previous studies established the role of SYK in tumor progression. Among its many targets, SYK can bind microtubules and other molecules associated with the cytoskeleton. We found SYK to be expressed in 6 of 10 ovarian carcinoma cell lines. Because of the ability of SYK to bind to microtubules, we studied the relationship of SYK expression to cellular migration. We examined several ovarian cancer cell lines that variably express SYK to elucidate the potential effects of SYK on cell migration. Our results demonstrate that knockdown of SYK expression by siRNA resulted in a decreased capability of cells to migrate using a traditional wound scratch assay. The duration of this effect was dependant upon cell line used suggesting that additional protein targets may be involved in the migratory process. The potential effects of SYK expression on invasion are currently being investigated. We will evaluate potential upstream and downstream targets to elucidate the pathway(s) responsible for SYK effects and compare within the cell lines examined. Understanding the growth signals and proteins potentially responsible for invasion and metastasis in ovarian cancer cell lines and tumor samples may eventually lead to new therapeutic approaches for ovarian cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1401. doi:10.1158/1538-7445.AM2011-1401
Coverage of Postprandial Blood Glucose Excursions With Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular Human Insulin in Subjects With Type 2 Diabetes
Authors: Klaus Rave, Tim Heise, Andreas Pfützner, Anders H. Boss
Journal: Diabetes Care (2007)

Technosphere Insulin (TI) is a formulation of regular human insulin (RHI) that provides efficient pulmonary administration (1) and demonstrates unique pharmacokinetic and pharmacodynamic properties compared with subcutaneous RHI, rapid-acting insulin analogs, and other inhaled insulins (2). Administration of TI results in a time to maximum insulin concentration of ∼15 min, with almost complete absorption within 3 h (3,4). With an onset of action comparable to intravenous insulin, TI represents the first formulation that approaches the physiological early insulin release. In this study, we evaluated the efficacy and safety of TI compared with subcutaneous RHI in covering prandial insulin needs. We measured blood glucose excursions after a meal challenge after individual titration of either insulin formulation during a 7-day treatment period in subjects with type 2 diabetes.

This prospective, open-label, randomized, two-period, cross-over study was conducted at one center (Profil Institute for Metabolic Research, Neuss, Germany). The study included a screening visit, 24-h in-house exposure to TI to establish initial dosing, two 7-day ambulant periods of daily mealtime TI or subcutaneous RHI separated by a 2- to 7-day washout, and a final visit. In-house meal challenges, using a standardized mixed meal with 496 kcal, were conducted at the end of each ambulant period. During treatment periods, each subject inhaled TI via a MedTone Model C Inhaler (MannKind Corporation, Valencia, CA) …
Segmented Erythrocytes Mistaken for Platelets-Reply
Authors: John R. Lindquist
Journal: JAMA (1982)

In Reply.—  The authors raise a valid point in that segmented erythrocytes may be occasionally mistaken for  when manual counting is done. However, the platelet quantitation done at our hospital is similar to that done in most major hospitals throughout the United States.  As clinicians, when platelet determinations are reported at 20,000 or less, we recognize that completely accurate determinations are not possible. Even if 50% of the platelets are in reality cellular fragments or debris, this does not negate a diagnosis of thrombocytopenia. When schistocytes and a hemolytic anemia are present, along with fever and transient neurological dysfunction, a clinical diagnosis of TTP can be made. We reported the case because the patient had the syndrome develop while taking an inhibitor of platelet aggregation, and the usual histological correlation was not present.
SPECIFIC MEDICATION IN TUBERCULOSIS OF MAN AND BEAST.
Authors: PAUL PAQUIN
Journal: JAMA (1897)

Specific medication in specific maladies is now recognized as the objective point of medical research. Whatever the means employed, the course of events and the processes to that end, the object sought is the all-important question. The men who have, or do now, play a rôle in the endeavors of medical science, no matter how divergent their opinions may be, no matter how inharmonious their relations, results and manner of work, are only instruments for the accomplishment of a great task, and their personality and differences, as in all processes of evolution, are insignificant and inconsiderable as compared with the achievements sought for the benefit of mankind. Conflicts of intellects are as essential factors of medical evolution as are conflicts of intellects in other
The Specific Serum Antimycobacterial Activity Test as a Guide to the Appropriate and Adequate Chemotherapy of Pulmonary Tuberculosis.
Authors: R. Gill
Journal: Annals of Internal Medicine (1961)

s1 May 1961The Specific Serum Antimycobacterial Activity Test as a Guide to the Appropriate and Adequate Chemotherapy of Pulmonary Tuberculosis.R. Gill, M.D., I. Kass, M.D., F.A.C.P., W. F. Russell Jr., M.D., W. E. Dye, Ph.D.R. Gill, M.D., I. Kass, M.D., F.A.C.P., W. F. Russell Jr., M.D., W. E. Dye, Ph.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-54-5-1055_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSerum microbiologic or chemical assay studies performed at National Jewish Hospital on antimicrobial agents such as streptomycin, isoniazid, cycloserine, pyrazinamide, and kanamycin, have clearly shown that patients achieve different serum concentrations of these antimicrobial agents even when dosages are adjusted according to body weight. Likewise, routine susceptibility studies have proved to be of value in determining the choice of the antituberculous drugs.Although they are practical and satisfactory, serum microbiologic assays and in vitro drug susceptibility studies do require personnel and equipment which may not always be readily available. In an effort to determine whether appropriate and adequate antimicrobial therapy... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: R. Gill, M.D.; I. Kass, M.D., F.A.C.P.; W. F. RussellJr., M.D.; W. E. Dye, Ph.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1961Volume 54, Issue 5Page: 1055-1055KeywordsAntimicrobialsAttentionBody weightChemotherapyDrugsIsoniazidStreptomycin ePublished: 1 December 2008 Issue Published: 1 May 1961 PDF downloadLoading ...
Myocarditis in β-Thalassemia Major
Authors: Dimitrios Th. Kremastinos, George Tiniakos, George N. Theodorakis, Demosthenes G. Katritsis, Pavlos K. Toutouzas
Journal: Circulation (1995)

Although acute pericarditis is a common complication of beta-thalassemia major, the prevalence and consequences of myocarditis in this disease have not been investigated.A prospective 5-year follow-up study was carried out in all patients with beta-thalassemia major in whom the diagnosis of acute infectious myocarditis could be established between 1977 and 1986. A similar number of age- and sex-matched control subjects with beta-thalassemia and normal left ventricular function and no evidence of myocarditis were also followed for 5 years. Of 1048 patients with beta-thalassemia major, 47 patients (age, 15 +/- 2.5 years) with precordial chest pain were diagnosed as having acute infectious myocarditis. Myocardial biopsy was diagnostic in 26 patients, border-line in 14 patients, and nondiagnostic in 7 patients. Acute heart failure with left ventricular dysfunction (left ventricular ejection fraction, 25 +/- 11%) developed in 11 patients (23.4%) with myocarditis, and 8 of them died within 1 month to 1 year after diagnosis. Thirteen patients with myocarditis (27.6%) developed chronic heart failure (left ventricular ejection fraction, 26 +/- 13%) within 3 +/- 1.3 years, and 10 of them died within 8 +/- 3 months. Left ventricular systolic and diastolic functions of the control subjects did not change significantly during the 5-year period (left ventricular ejection fraction, 63 +/- 11% versus 65 +/- 7%; P = NS). However, left ventricular restrictive abnormalities (early diastole/late diastole, > 2.2; deceleration time, < 110 milliseconds) combined with right ventricular dilatation (> 30 mm internal diameter) and right-sided heart failure developed in 3 patients with extremely high mean serum ferritin levels. No significant difference was found in mean levels of serum ferritin and pretransfusion hemoglobin between patients with and those without myocarditis.In patients with beta-thalassemia, myocarditis appears to be involved in the pathogenesis of left ventricular systolic dysfunction, being the main cause of death. Iron overload appears to provoke left ventricular restrictive abnormalities combined with right ventricular enlargement and dysfunction.